Aptamer Array Finds Metabolic Changes from Hepatoxicity

Information

  • Research Project
  • 6729940
  • ApplicationId
    6729940
  • Core Project Number
    R43CA101682
  • Full Project Number
    5R43CA101682-02
  • Serial Number
    101682
  • FOA Number
    PA-02-75
  • Sub Project Id
  • Project Start Date
    4/1/2003 - 21 years ago
  • Project End Date
    9/30/2005 - 19 years ago
  • Program Officer Name
    GRABB, MARGARET C.
  • Budget Start Date
    4/1/2004 - 20 years ago
  • Budget End Date
    9/30/2005 - 19 years ago
  • Fiscal Year
    2004
  • Support Year
    2
  • Suffix
  • Award Notice Date
    3/24/2004 - 20 years ago

Aptamer Array Finds Metabolic Changes from Hepatoxicity

DESCRIPTION (provided by applicant): In order to reduce the costs of drug development and improve methods of detecting environmental effects of xeniobiotics, there is a need for in vitro methods of xeniobiotics identifying toxicity of materials to specific organs that do not require a whole-animal model. In particular, methods capable of identifying hepatotoxicity either require extensive animal studies or do not take into account differences in metabolic pathways that cannot be predicted by genomic approaches. American Research Corporation of Virginia (ARCOVA) proposes the development of a novel sensitive aptamer array that is capable of differentiating multiple metabolic products on a real-time basis through metabonomics. This proposal is innovative in developing an aptamer array having improved selectivity and sensitivity to changes of low molecular weight metabolic products resulting from hepatotoxicity in the cell culture. Phase I specific aims include preparation of liver metabolite-specific capture aptamers and capture aptamer-analyte probe aptamers for fabrication of surface-sensitive diode laser (SSDL) array elements, modification of SSDL aptamer array to improve sensitivity and reproducibility, design and fabrication of experimental workstation for the characterization of an engineering model SSDL array sensor head and acquisition of families of test data from an SSDL array and optimization of an engineering model for the metabolic monitor. In Phase II of the program, a prototype strip panel will be constructed and field-tested in preparation for commercialization during Phase III of the program. Successful completion of the Phase I program will result in an SSDL-based aptamer array for detection of hepatotoxicity-related metabolic products. The aptamer array will find commercial use in biomedical point-of-care monitoring, evaluation of treatment protocols and veterinary medicine.

IC Name
NATIONAL CANCER INSTITUTE
  • Activity
    R43
  • Administering IC
    CA
  • Application Type
    5
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    234400
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    395
  • Ed Inst. Type
  • Funding ICs
    NCI:234400\
  • Funding Mechanism
  • Study Section
    ZCA1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    AMERICAN RESEARCH CORP OF VIRGINIA
  • Organization Department
  • Organization DUNS
    130534357
  • Organization City
    RADFORD
  • Organization State
    VA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    241433406
  • Organization District
    UNITED STATES